Ilan Ganot - Solid Biosciences CEO, Co-Founder, Director
| SLDB Stock | USD 5.29 0.29 5.20% |
CEO
Mr. Ilan Ganot is the President, Chief Executive Officer, CoFounder, Director of the Company. Mr. Ganot has served as our President since June 2018. Previously, Mr. Ganot served as an investment banker at JPMorgan Chase Co., a leading global financial services firm, from September 2011 to September 2013. From October 2008 to August 2011, Mr. Ganot served as a banker at Nomura Securities Co., Ltd., a securities and investment banking company, and from September 2003 to September 2008, at Lehman Brothers, a global financial services firm. Mr. Ganot received his M.B.A. from London Business School and holds law and business degrees from the Interdisciplinary Center in Herzliya, Israel. Mr. Ganot also practiced corporate law in Israel and was a Captain in the Israeli Defense Forces. He is qualified to serve on our board of directors because of his personal dedication to improving treatments available for DMD patients and his extensive leadership experience. since 2019.
| Age | 51 |
| Tenure | 6 years |
| Professional Marks | MBA |
| Address | 500 Rutherford Avenue, Charlestown, MA, United States, 02129 |
| Phone | 617 337 4680 |
| Web | https://www.solidbio.com |
Latest Insider Transactions
Ganot received his MBA from London Business school and holds law and business degrees from the IDC in Herzliya, Israel.Ilan Ganot Latest Insider Activity
Tracking and analyzing the buying and selling activities of Ilan Ganot against Solid Biosciences stock is an integral part of due diligence when investing in Solid Biosciences. Ilan Ganot insider activity provides valuable insight into whether Solid Biosciences is net buyers or sellers over its current business cycle. Note, Solid Biosciences insiders must abide by specific rules, including filing SEC forms every time they buy or sell Solid Biosciences'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Ilan Ganot over a week ago Disposition of 4861 shares by Ilan Ganot of Solid Biosciences subject to Rule 16b-3 | ||
Ilan Ganot over two weeks ago Acquisition by Ilan Ganot of 3883 shares of Solid Biosciences subject to Rule 16b-3 | ||
Ilan Ganot over three weeks ago Disposition of 1142 shares by Ilan Ganot of Solid Biosciences at 5.2999 subject to Rule 16b-3 | ||
Ilan Ganot over three weeks ago Disposition of 144 shares by Ilan Ganot of Solid Biosciences at 3.1096 subject to Rule 16b-3 |
Solid Biosciences Management Efficiency
The company has return on total asset (ROA) of (0.3533) % which means that it has lost $0.3533 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6579) %, meaning that it created substantial loss on money invested by shareholders. Solid Biosciences' management efficiency ratios could be used to measure how well Solid Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. As of February 27, 2025, Return On Tangible Assets is expected to decline to -0.7. In addition to that, Return On Capital Employed is expected to decline to -0.84. At present, Solid Biosciences' Net Tangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 42.5 M, whereas Total Assets are forecasted to decline to about 152.1 M.Similar Executives
| Found 11 records | CEO Age | ||
| Arnon Rosenthal | Alector | 69 | |
| Carole MD | Larimar Therapeutics | 66 | |
| Richard Cunningham | Anebulo Pharmaceuticals | 54 | |
| Jon Congleton | Mineralys Therapeutics, Common | 62 | |
| William MD | Passage Bio | 52 | |
| Mark Goldsmith | Revolution Medicines | 63 | |
| Kevin Koch | Edgewise Therapeutics | 65 | |
| Nadim Ahmed | Cullinan Oncology LLC | 57 | |
| Markus MD | Monte Rosa Therapeutics | 53 | |
| Andrew MBA | C4 Therapeutics | 54 | |
| PharmD MBA | Century Therapeutics | N/A | |
Management Performance
| Return On Equity | -0.66 | ||||
| Return On Asset | -0.35 |
Solid Biosciences LLC Leadership Team
Elected by the shareholders, the Solid Biosciences' board of directors comprises two types of representatives: Solid Biosciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Solid. The board's role is to monitor Solid Biosciences' management team and ensure that shareholders' interests are well served. Solid Biosciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Solid Biosciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Alexander Cumbo, CEO President | ||
| Gabriel MD, Chief Officer | ||
| Gilad Hayeem, President Co-Founder, Director | ||
| Shuli MD, Head Development | ||
| Ilan Ganot, CEO, Co-Founder, Director | ||
| Paul Herzich, Chief Officer | ||
| Caitlin Lowie, VP IR | ||
| Matthew Arnold, Independent Director | ||
| Allison JD, Senior Resources | ||
| Carl Morris, Chief Scientific Officer | ||
| Kevin CFA, CFO Treasurer | ||
| ACA ACA, Ex Chair | ||
| Andrey Zarur, Chairman of the Board, Co-Founder | ||
| Erin Brennan, Chief Sec | ||
| JD Howton, Chief Officer | ||
| MBA MBA, Treasurer CFO | ||
| CPA ACA, Executive Chair | ||
| Stephen MBA, Treasurer Officer | ||
| Annie Ganot, CoFounder Advocacy | ||
| Jessie Hanrahan, Chief Officer |
Solid Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Solid Biosciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.66 | ||||
| Return On Asset | -0.35 | ||||
| Current Valuation | 257.33 M | ||||
| Shares Outstanding | 76.32 M | ||||
| Shares Owned By Insiders | 0.45 % | ||||
| Shares Owned By Institutions | 55.53 % | ||||
| Number Of Shares Shorted | 2.65 M | ||||
| Price To Book | 2.42 X | ||||
| Price To Sales | 3.65 X | ||||
| Gross Profit | (76.56 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Solid Biosciences LLC offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Solid Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Solid Biosciences Llc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Solid Biosciences Llc Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Solid Biosciences LLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Solid Biosciences. If investors know Solid will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Solid Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Solid Biosciences LLC is measured differently than its book value, which is the value of Solid that is recorded on the company's balance sheet. Investors also form their own opinion of Solid Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Solid Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Solid Biosciences' market value can be influenced by many factors that don't directly affect Solid Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Solid Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Solid Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Solid Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.